Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of September 7th – 13th, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
10. This UK-Based Psychedelics Company is Ready to Go Public on the NASDAQ
In Yet Another Sign That Psychedelics Are Making Their Way Into the Mainstream, Compass Pathways Has Filed for its Initial Public Offering (IPO) on the NASDAQ Stock Exchange
The London-based Compass Pathways, which will trade under the ticker symbol ‘CMPS,’ is backed by some serious heavyweights, including lead investor Christian Angermayer and well-known Silicon Valley tech billionaire Peter Thiel.
READ FULL COMPASS PATHWAYS ARTICLE
9. Want to Lose $1.8 Billion? Invest in Aurora Cannabis Stock
On Tuesday, Aurora Announced a Potentially Massive 1.8 Billion Write-Down for Q4
Simultaneously, Aurora Cannabis (TSX: ACB) (NYSE: ACB) (FRA: 21P) announced it has chosen a new CEO, its Chief Commercial Officer Miguel Martin. The market reacted with shock, sending ACB Stock down 12% before recovering.
READ FULL AURORA CANNABIS ARTICLE
8. Psychedelics Company Havn Life Sciences Debuts on CSE
The Company is Led By Co-CEOs Susan Chapelle and Tim Moore, the Former CEO of Cannabis Company Green Growth Brands
Havn Life Sciences (CSE: HAVN), a recently-formed Psychedelics company, announced on Tuesday its debut on the Canadian Securities Exchange (CSE) under the symbol HAVN.
7. CIBC: Cronos Group CEO Switch Up is “Somewhat Surprising”
In a Note from CIBC, Analyst John Zamparo Comments, “CEO Transition – Doubling Down On Consumer Focus”
This past week, Cronos Group (TSX: CRON) (NASDAQ: CRON) (FRA: 7CI) announced that its Board of Directors has appointed Kurt Schmidt as President and Chief Executive Officer of the Company and that Mike Gorenstein has been appointed Executive Chairman. Mike Gorenstein served as the Chairman, President, and CEO of Cronos since 2016.
READ FULL CRONOS GROUP ARTICLE
6. 3 Psychedelic Stocks to Buy for HUGE Gains in the Shroom Boom
Psychedelic Drugs Are Losing Their Negative Stigma, Paving the Way for Major Gains in Psychedelic Stocks
What will drive this Shroom Boom of the 2020s? The same things that drove the cannabis boom of the 2010s. Changing science. Changing consumer attitudes. And, changing laws. With that in mind, some of the best Psychedelic Stocks to buy for potentially huge gains are MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: BGHM), Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) and Revive Therapeutics (CSE: RVV) (OTCPK: RVVTF) (FRA: 31R).
READ FULL PSYCHEDELIC STOCKS ARTICLE
5. The 3 Most Exciting Pot Stocks You’re Overlooking
These Cannabis Stocks Aren’t Getting a Lot of Attention Yet, But They Soon Will Be
If you want truly exciting Pot Stocks that aren’t yet on many investors’ radars, then take a gander at these three Cannabis companies: TerrAscend (CSE: TER) (OTCQX: TRSSF), Planet 13 (CSE: PLTH) (OTCQX: PLNHF) and Jushi Holdings (CSE: JUSH) (OTCQB: JUSHF).
4. Havn Life Sciences Granted Section 56 Exemption to Begin Scientific Work With Psilocybin
Havn Life Will Develop Methods for Safe, Standardized, Quality- Controlled Production of Medical Compounds Extracted From the Psilocybe Spp. Mushroom
Havn Life Sciences (CSE: HAVN) announced that its wholly-owned subsidiary, HAVN Research Inc., was granted a Section 56 exemption by Health Canada, pursuant to which it now has the ability to possess certain amounts of pure Psilocybin for scientific purposes, specifically for the research and development of quality control methods.
3. Canopy Growth Launches Martha Stewart CBD Line
Initially, the Line Consists of Four Products Containing the Popular Substance
One of America’s top lifestyle gurus has taken the plunge into marijuana-related goods. Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) announced in a press release that it has launched Martha Stewart CBD, a new line of comestibles infused with cannabidiol (CBD).
READ FULL CANOPY GROWTH ARTICLE
2. Why Investing in Psychedelic Medicine Could Be Better Than Cannabis
Psychedelic Companies Are Seeking FDA Approval to Develop Drugs to Treat Mental Health Disorders
The burgeoning Psychedelic sector is attracting attention from investors as more companies have gone public, and research has increased rapidly due to greater mainstream and government acceptance and decriminalization.
READ FULL PSYCHEDELICS INVESTING ARTICLE
1. 3 Top Marijuana Stocks to Buy in September
These Cannabis Stocks Have at Least Two Things in Common: A Focus on the U.S. Market and Tremendous Growth
Quite a few Cannabis Stocks that focus on the U.S. market have delivered fantastic performances in 2020. Some of them appear to be poised to keep the good times rolling. Here are three top marijuana stocks to buy in September: Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2), GrowGeneration (NASDAQ: GRWG) and Innovative Industrial Properties (NYSE: IIPR).
READ FULL TOP MARIJUANA STOCKS ARTICLE
With U.S. Pot Stocks the Hot Theme of 2021, Here’s Why Red White & Bloom Could Be One of the Cannabis Sector’s Top Performers
Follow TCI on Social Media: Facebook | Instagram | Twitter | LinkedIn | Investor Group
Follow Psychedelic Profits on Social Media: Facebook | Twitter | LinkedIn | Investor Group
Did you enjoy this article? If so, sign up for our Email Newsletter below to start receiving our weekly recap of the week’s best articles.
Get Your Copy of The Ultimate Cannabis Investing Guide
Join the Discussion in the TCI Investor Group
Featured ArticlesCannabis Stock NewsCannabis Industry ArticlesTechnical Analysis ArticlesWatch Cannabis Stock Videos